Good afternoon :)
Place Order
Add to Watchlist

Sun Pharmaceutical Industries Ltd

SUNPHARMA

Sun Pharmaceutical Industries Ltd

SUNPHARMA
Health CarePharmaceuticals
LargecapWith a market cap of ₹4,40,517 cr, stock is ranked 14
Low RiskStock is 1.40x as volatile as Nifty
1,846.900.59% (+10.90)
1,846.900.59% (+10.90)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
LargecapWith a market cap of ₹4,40,517 cr, stock is ranked 14
Low RiskStock is 1.40x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
LargecapWith a market cap of ₹4,40,517 cr, stock is ranked 14
Low RiskStock is 1.40x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
42.406.560.74%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.236.560.48%

Forecast & Ratings

Detailed Forecast 
76%
Analysts have suggested that investors can buy this stock

from 33 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Sun Pharmaceutical Industries Limited is a pharmaceuticals company which offers generics, branded generics, specialty products, over-the-counter products, anti-retroviral and APIs.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 10.64%, vs industry avg of 9.04%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 13.7% to 13.23%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 29.15%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue29,145.2832,201.5927,328.2230,091.4033,489.0934,357.3139,729.9644,520.2049,887.1750,891.06
Raw Materialssubtract6,724.158,402.377,193.988,302.088,929.609,328.3010,459.1511,349.0710,370.4836,081.23
Power & Fuel Costsubtract545.44525.09559.97613.60621.89627.09702.78830.05760.78
Employee Costsubtract4,772.314,902.305,367.055,967.096,362.356,862.237,300.838,296.039,429.06
Selling & Administrative Expensessubtract5,219.205,224.614,727.005,350.336,995.376,283.417,366.889,482.3611,033.19
Operating & Other expensessubtract3,752.782,434.803,983.833,739.603,214.786,235.537,147.912,452.834,410.66
Depreciation/Amortizationsubtract1,037.531,264.751,499.841,753.252,052.782,079.952,143.742,529.432,556.642,560.45
Interest & Other Itemssubtract523.24399.80517.57555.25302.73141.43127.35172.00238.47219.13
Taxes & Other Itemssubtract2,024.922,083.501,383.281,144.781,244.66-104.451,208.59934.851,511.511,640.79
EPS20.3028.988.7311.1115.6912.1013.6435.3239.9143.30
DPS1.003.502.002.754.007.5010.0011.5013.5012.50
Payout ratio0.050.120.230.250.250.620.730.330.340.29

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2014

Annual Report Unavailable

Investor Presentation

Apr 7PDF
FY 2015

Annual Report Unavailable

Investor Presentation

Mar 25PDF
FY 2016

Annual Report Unavailable

FY 2017

Annual Report Unavailable

FY 2018

Annual Report Unavailable

FY 2019

Annual Report Unavailable

FY 2022

Annual report

PDF

Investor Presentation

Mar 24PDF
FY 2023

Annual report

PDF

Investor Presentation

Apr 28PDF
Jan 16PDF
Sep 16PDF
FY 2024

Annual report

PDF

Investor Presentation

Sep 11PDF
Jul 21PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Sun Pharmaceutical Industries Ltd46.006.560.74%
Cipla Ltd32.364.980.79%
Torrent Pharmaceuticals Ltd68.6516.580.83%
Dr Reddy's Laboratories Ltd19.613.870.61%

Price Comparison

Compare SUNPHARMA with any stock or ETF
Compare SUNPHARMA with any stock or ETF
SUNPHARMA
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding54.48%12.78%6.50%17.23%9.01%

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Shareholding History

MarJunSepDec '23MarJun12.91%13.16%13.07%12.93%12.21%12.78%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Sun Pharmaceutical Industries Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
ICICI Prudential Value Discovery Fund - Growth - Direct Plan

Growth
0.5937%5.21%-0.28%8/93 (0)
ICICI Prudential Bluechip Fund - Growth - Direct Plan

Growth
0.4161%2.85%0.28%11/82 (0)
ICICI Prudential Equity & Debt Fund - Direct Plan - Growth

Growth
0.3740%4.11%0.18%5/185 (+1)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Sun Pharmaceutical Industries Ltd

Events

Dividend Trend

Increasing Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

SUNPHARMA has increased dividends consistently over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.74%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹7.35 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJul 12, 2024

Final
Final | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Jul 12, 2024

Cash Dividend

Ex DateEx DateFeb 9, 2024

Interim
Interim | Div/Share: ₹8.50

Dividend/Share

8.50

Ex DateEx Date

Feb 9, 2024

Cash Dividend

Ex DateEx DateJul 28, 2023

Final
Final | Div/Share: ₹4.00

Dividend/Share

4.00

Ex DateEx Date

Jul 28, 2023

Cash Dividend

Ex DateEx DateFeb 8, 2023

Interim
Interim | Div/Share: ₹7.50

Dividend/Share

7.50

Ex DateEx Date

Feb 8, 2023

Cash Dividend

Ex DateEx DateAug 19, 2022

Final
Final | Div/Share: ₹3.00

Dividend/Share

3.00

Ex DateEx Date

Aug 19, 2022

News & Opinions
Corporate
Sun Pharma and Israel-based Moebius Medical announce USFDA grant of Fast Track designation to MM-II

Sun Pharmaceutical Industries and Israel-based Moebius Medical announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to MM-II (Large Liposomes of DPPC and DMPC) for the treatment of osteoarthritis knee pain. Planning for confirmatory Phase 3 clinical trials for MMII is underway. The FDA's Fast Track program is designed to facilitate the development and expedite the review of therapies intended to treat serious conditions and address unmet medical needs in order to potentially bring important new medicines to patients earlier. Among other benefits, companies whose investigational products are granted FTD are eligible for more frequent interactions with the FDA during clinical development and potentially accelerated approval and/or priority review. 'As we enter Phase 3 development, we are very encouraged by the FDA's decision to grant Fast Track designation to MM-II and recognize its potential to fill an unmet medical need for patients suffering from Osteoarthritis,' said Marek Honczarenko, MD, PHD, Senior Vice President, Head Global Development at Sun Pharma.Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Sun Pharma, Moebius Medical gets USFDA FTD to MM-II

MM-II is a novel non-opioid product that uses a proprietary suspension of large, empty, multilamellar liposomes which are intended to reduce friction and wear on the joint and thus relieve joint pain. The company and Moebius Medical jointly developing this product, have announced plans to initiate a Phase 3 clinical program and to seek a CE Mark for the product in the European Union. The FDA's Fast Track program is designed to facilitate the development and expedite the review of therapies intended to treat serious conditions and address unmet medical needs in order to potentially bring important new medicines to patients earlier. Among other benefits, companies whose investigational products are granted FTD are eligible for more frequent interactions with the FDA during clinical development and potentially accelerated approval and/or priority review. Marek Honczarenko, MD, PHD, senior vice president, Head Global Development, Sun Pharma, said, 'As we enter Phase 3 development, we are very encouraged by the FDA's decision to grant Fast Track designation to MM-II and recognize its potential to fill an unmet medical need for patients suffering from Osteoarthritis.' Moshe Weinstein, CEO of Moebius Medical, added, 'This Fast Track Designation, which will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II, and follows our recently released Phase 2b data, which showed MMII's potential to provide effective and durable treatment for patients with knee pain of Osteoarthritis.' Moebius Medical is a clinical stage biotechnology company that is developing novel pain relief treatments for osteoarthritis Sun Pharmaceuticals Industries is a leading global pharmaceutical company with specialty and generic presence and India's top pharma company. The company's consolidated net profit jumped 40.20% to Rs 2,835.6 crore on 5.96% rise in revenue from operations to Rs 12,652.75 crore in Q1 FY25 over Q1 FY24. The script rose 0.29% to Rs 1,825.75 on the BSE.Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Sun Pharma launches Tedizolid Phosphate tablets 200 mg in India

Sun Pharmaceutical Industries has launched Tedizolid Phosphate tablets 200 mg in India under the brand name 'STARIZO'. STARIZO (Tedizolid Phosphate) is a novel, oxazolidinone-class antibacterial, used to treat Acute Bacterial Skin and Skin Structure Infection (ABSSSI). Sun Pharma has obtained rights from Merck Sharp & Dohme Singapore Trading to develop, manufacture and commercialise Tedizolid Phosphate in India. Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Spotlight
Sun Pharmaceuticals Industries Ltd spurts 0.31%, up for fifth straight session

Sun Pharmaceuticals Industries Ltd gained for a fifth straight session today. The stock is quoting at Rs 1753.25, up 0.31% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.53% on the day, quoting at 24703.35. The Sensex is at 80851.87, up 0.53%. Sun Pharmaceuticals Industries Ltd has gained around 10.45% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceuticals Industries Ltd is a constituent, has gained around 7.94% in last one month and is currently quoting at 22237.85, up 0.19% on the day. The volume in the stock stood at 7.58 lakh shares today, compared to the daily average of 25.56 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1752.95, up 0.3% on the day. Sun Pharmaceuticals Industries Ltd is up 54.15% in last one year as compared to a 27.38% jump in NIFTY and a 45.31% jump in the Nifty Pharma index.The PE of the stock is 150.65 based on TTM earnings ending June 24.Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Corporate
Sun Pharmaceutical to invest USD 15 mn in Pharmazz Inc.

Sun Pharmaceutical Industries has entered into an agreement with Pharmazz Inc. Delaware US, pursuant to which Sun Pharma has agreed to invest upto $15 Mn investment resulting in more than 5% holding in Pharmazz Inc. Pharmazz Inc (Pharmazz) is a Delaware, US corporation based in Willowbrook Illinois, US and is a biopharmaceutical company developing its two leading drug candidates, Sovateltide for treatment of acute cerebral ischemic stroke and Centhaquine for treatment of hypovolemic shock. Both products are approved in India and marketed through partners under brands, Tyvalzi (Sovateltide) and Lyfaquin (Centhaquine) and are being developed for USA and other markets. Sun Pharma shall also receive the exclusive right to license Sovateltide for marketing & distribution in certain emerging market countries. Powered by Capital Market - Live

1 month agoCapital Market - Live

Sun Pharmaceutical Industries Share Price Live Updates: Sun Pharma Closes at Rs 1720.35 with 8145 Shares Traded, 7-Day Avg Volume at 3,307,395 Shares - The Economic Times

1 month agoEconomic Times
Sun Pharma is showing signs of a continuation of uptrend: Ruchit Jain
1 month agoThe Economic Times

Sun Pharma is showing signs of a continuation of uptrend: Ruchit Jain

1 month agoEconomic Times

Technical Breakout Stocks: Sun Pharma, Ajanta Pharma and JB Chemicals hit record high when Sensex falls 2,200 points - Market Roundup

1 month agoEconomic Times

Sun Pharma, Suzlon Energy among 5 stocks hitting new 52-week highs amid Monday’s heavy sell-off - Rising High

1 month agoEconomic Times